The European Congress of Endocrinology is the European Society of Endocrinology’s premier event
It was a pleasure to attend the ECE 2022 in Milan as members of the Androlabs team from Spain, Germany, the UK and Ireland had the opportunity to speak to thought leaders in the endocrinology sphere.
Some of our key take aways included:
In May the Androlabs team attended the European Congress of Endocrinology in Istanbul. Below we've included 5 takeaways for you to review. If you have questions, or would like more content about the sessions, please don't hesitate to reach out.
1. Global collaboration is critical to improve outcomes for all
As a global pharmaceutical company, we understand the importance of learning from the similarities and differences we find across countries. Richard Quinton, Giulia Rastrelli and others made reference to the The European Male Ageing Study (EMAS), which involved more than 3 thousand men from across 8 countries. Thousands of attendees from more than 15 countries attended ECE - the future of international collaboration looks bright.
2. There are significant challenges - especially facing men's health
How do we sustainably address obesity, poor lifestyle and diets? The interconnected nature of hypogonadism with multiple co-morbidities was discussed frequently, alongside the benefits of testosterone replacement therapy.
Cross-specialty collaboration is a challenge - no less than five specialties are involved in the journey of this 55-year-old man: For men to get treated, cross-specialty collaboration is needed - as seen by our own illustrative patient journey in the image below:
3. Nurses are critical to improving quality of life and outcomes; more recognition is needed
Further to the great success of the "Nurses Clinical Workshops", we can see that while the experience of nurses across countries is not homogenous, their impact is clear. One example can be seen in this study of patient outcomes, focused on rheumatology patients. The ESE Nurse Committee, chaired by Sherwin Criseno, is looking to expand its base to further the education and best-practice sharing of nurses across Europe which is sure to have a positive impact on patient outcomes.
4. There have been numerous exciting new developments... From research into a fascinating biomarker (INSL3) and new applications for kisspeptin (including Hypoactive Sexual Desire Disorder) - there is much to be excited about. New approaches to behavioural change in patients e.g., "Snacktivity" were also explored.
5. ...but more evidence is needed
Lectures and questions from the global audience often ended with the refrain that further research is needed - from optimum osteoporosis treatment regimes, TSBs and more. One frequently referenced study was the TRAVERSE study, which will soon be reporting on the links between cardiovascular risk and testosterone replacement therapy - which in addition to this Imperial study, should provide more clarity for endocrinologists and patients.
We're already looking forward to ECE 2024 in Sweden and hope to see you there!
P.S. Have you explored TRTed?
Practical, balanced, and evidenced-based resources on men’s health, supported by Androlabs. Listen here to the latest interview with Dr. Edouard Mills who discusses his research on kisspeptin and HSDD, and join the TRTed Community here.